News
Innovative Cellular Therapeutics
Innovative Cellular Therapeutics to Present New Clinical Data with CoupledCAR® CAR-T in Colon Cancer at the LifeSci Partners Private Company Virtual Summer Symposium on August 5, 2020 470 631 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics to Present New Clinical Data with CoupledCAR® CAR-T in Colon Cancer at the LifeSci Partners Private Company Virtual Summer Symposium on August 5, 2020

ROCKVILLE, Md., July 28, 2020 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for solid and liquid tumors, today announced that it will present new clinical data at the LifeSci Partners Private Company Virtual Summer Symposium on August 5, 2020.…

Innovative Cellular Therapeutics Announces Details of Two Abstracts on its Novel CoupledCAR® Solid Tumor CAR-T Technology to be Presented Orally at the 23rd American Society of Gene & Cell Therapy Meeting 1719 1732 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics Announces Details of Two Abstracts on its Novel CoupledCAR® Solid Tumor CAR-T Technology to be Presented Orally at the 23rd American Society of Gene & Cell Therapy Meeting

ROCKVILLE, Md., April 29, 2020 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for solid and liquid tumors, today announced details of two abstracts on its novel CoupledCAR® solid tumor CAR-T technology for treating colorectal and thyroid cancers. The abstracts…

Innovative Cellular Therapeutics Announces Acceptance of Abstract on its Novel CoupledCAR® Technology for Treating Colorectal Cancer for Oral Presentation at the 23rd American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 1300 1625 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics Announces Acceptance of Abstract on its Novel CoupledCAR® Technology for Treating Colorectal Cancer for Oral Presentation at the 23rd American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

ROCKVILLE, Md., April 14, 2020 — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for solid and liquid tumors, today announced acceptance of its abstract titled Novel CoupledCAR® Technology for Treating Colorectal Cancer. The abstract will be presented orally at the 23rd American…

Maryland Tech Council Announces Nomination of Innovative Cellular Therapeutics as “Emerging Life Sciences Company of the Year” Finalist 1745 1664 Innovative Cellular Therapeutics

Maryland Tech Council Announces Nomination of Innovative Cellular Therapeutics as “Emerging Life Sciences Company of the Year” Finalist

ROCKVILLE, Md., March 10, 2020 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for solid and liquid tumors, announced today that it has been nominated as a finalist for “Emerging Life Sciences Company of the Year,” by Maryland Tech…

Innovative Cellular Therapeutics Appoints Cell and Gene Therapy Manufacturing Expert Christopher Ballas, Ph.D., as SVP of Manufacturing 1366 911 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics Appoints Cell and Gene Therapy Manufacturing Expert Christopher Ballas, Ph.D., as SVP of Manufacturing

ROCKVILLE, Md., January 07, 2020 — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for liquid and solid tumors, today announced the appointment of Christopher Ballas, Ph.D., as Senior Vice President of Manufacturing. Dr. Ballas previously served in senior manufacturing roles at Rocket Pharmaceuticals and WuXi AppTec, with a focus on gene and cell-based therapies.  “Our need for quality vector…

Innovative Cellular Therapeutics Secures Equity Financing to Advance its Next Generation Liquid and Solid Tumor CAR-T Programs 1366 907 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics Secures Equity Financing to Advance its Next Generation Liquid and Solid Tumor CAR-T Programs

ROCKVILLE, Md., Dec. 17, 2019 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for liquid and solid tumors, today announced that it has closed a U.S. dollar Series B+ equity financing for an undisclosed amount. The lead investor, LH Ventures,…

Innovative Cellular Therapeutics Strengthens Executive Leadership Team with Appointment of Morten Marott as Chief Financial Officer 1366 911 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics Strengthens Executive Leadership Team with Appointment of Morten Marott as Chief Financial Officer

ROCKVILLE, Md., December 5, 2019 — Innovative Cellular Therapeutics (ICT), a biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for liquid and solid tumors, today announced the appointment of Morten Marott, who joined ICT as Chief Financial Officer in July 2019. Mr. Marott was formerly Chief Financial Officer of…

Innovative Cellular Therapeutics Announces FDA Clearance of IND for its Dominant Negative PD-1 “Armored” Next Generation CAR-T Cell Therapy 3000 2250 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics Announces FDA Clearance of IND for its Dominant Negative PD-1 “Armored” Next Generation CAR-T Cell Therapy

ROCKVILLE, Md., December 4, 2019 — Innovative Cellular Therapeutics (ICT), a biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for blood cancers and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ICTCAR014, a next generation CD19-targeting…

Innovative Cellular Therapeutics Announces Data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 805 612 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics Announces Data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

ICT’s lead “armored” CAR-T program, ICTCAR014, demonstrated responses in two patients treated for refractory diffuse large B-cell lymphoma (DLBCL) in an investigator-sponsored clinical trial in China; safe and well-tolerated Currently in preclinical development in the U.S. for the treatment of Non-Hodgkin Lymphoma ROCKVILLE, Md., May 08, 2019 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a biotechnology…

Innovative Cellular Therapeutics Announces Successful Completion of Pre-IND Meeting With FDA 1366 911 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics Announces Successful Completion of Pre-IND Meeting With FDA

ROCKVILLE, Md., March 19, 2019 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a biotechnology company developing cellular immunotherapies for the treatment of cancer, today announced it has successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA). At the meeting, the FDA provided feedback regarding ICT’s planned initiation of…

  • 1
  • 2